GSEP
COLL icon

Golden State Equity Partners’s Collegium Pharmaceutical COLL Stock Holding History

Golden State Equity Partners’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30
Closed -$992 – 603
2026
Q1 		$992 Buy
+30
New +$1.27K ﹤0.01% 1793

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Golden State Equity Partners's COLL Position: Q2 2026 in Review

Golden State Equity Partners sold out of Collegium Pharmaceutical (COLL) in Q2 2026, closing a stake of 30 shares — an estimated $992 sold.

Golden State Equity Partners first reported a position in COLL in Q1 2026 and held it in 1 quarter. The position peaked at $992 in Q1 2026. 280 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Golden State Equity Partners reported no remaining Collegium Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 30 Collegium Pharmaceutical shares in Q2 2026, an estimated $992.
  • Golden State Equity Partners first reported a position in Collegium Pharmaceutical in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Collegium Pharmaceutical position peaked at $992 in Q1 2026.
  • 280 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.